600645.SH
Vcanbio Cell & Gene Engineering Corp., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 17.61
+3.89%Oct 29, 2026, 11:02 UTC
Zhongyuan Union reported revenue of 1.013 billion yuan and net profit attributable to shareholders of 107 million yuan for the first three quarters of 2026.
Source:Oct 29, 2026, 11:02 UTC
Zhongyuan Union reported third-quarter 2026 revenue of 354 million yuan, down 5.98% year over year, and net profit attributable to shareholders of 45.5648 million yuan, down 9.12%.
Source:Sep 15, 2026, 09:14 UTC
China Securities Regulatory Commission Tianjin Regional Bureau issued warning letters to Zhongyuan Xiehe and its chairman Gong Hongjia, general manager Wang Hongqi, and then-board secretary Chen Yiqing over untrue and inaccurate disclosure of related-party leasing transactions.
Source:Aug 18, 2026, 03:29 UTC
ACME Solar Holdings completed INR 21.47 billion in refinancing to redeem non-convertible debentures issued by 12 operational solar project SPVs with a combined capacity of 450MW, and fully redeemed its underlying offshore dollar bonds.
Source:Jul 30, 2026, 09:38 UTC
Zhongyuan Xiehe obtained a Class III medical device registration certificate in February 2026.
Source:Jul 17, 2026, 07:43 UTC
Zhongyuan Xiehe's subsidiary Wuhan Optics Valley Zhongyuan Pharmaceutical enrolled the first subject for multiple-dose administration in Phase I of the I/II clinical trial of VUM02 injection for acute graft-versus-host disease.
Source: